Citing liver damage, Pfizer withdraws Thelin

December 10, 2010

(AP) -- Pfizer Inc. said Friday it is pulling its blood pressure drug Thelin off the market and stopping all clinical trials because the drug can cause fatal liver damage.

Thelin is sold in the European Union, Canada, and Australia as an oral treatment for severe pulmonary arterial hypertension, or in the pulmonary artery. Pfizer said a review of data from and post-marketing reports showed a new link to liver injury. It also consulted with experts about the link between Thelin and the deaths of two patients.

Liver damage was a known side effect of Thelin and similar drugs, the company said. Pfizer said the withdrawal was voluntary and added that it has withdrawn its filing for marketing approval in the U.S.

Since there are other treatment options, Pfizer said the benefits of Thelin don't outweigh the risks. It is stopping all studies of the oral drug, which Pfizer acquired in 2008 when it bought Encysive Pharmaceuticals Inc. Encysive had been trying to win marketing approval for Thelin since 2005, but the said it was not effective enough. Other agencies only approved the drug for that was so debilitating that patients' physical activity was severely limited.

The chemical name of Thelin is sitaxsentan.

In premarket trading, shares of Pfizer shed 9 cents to $16.67 from Thursday's close of $16.76.

Explore further: Pfizer heart pill to be standalone therapy

0 shares

Related Stories

Pfizer drug found with serious side effect

November 1, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

Viracept caution issued by Pfizer

September 10, 2007

Pfizer Inc. issued a "Dear Healhcare Professional" letter Monday warning of the presence of an impurity in its Viracept medication.

Pfizer gets EU approval for kids' cholesterol drug

July 6, 2010

(AP) -- The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides, a type of blood fat, Pfizer said Tuesday.

FDA approves larger dose of Pfizer's Aricept

July 25, 2010

(AP) -- Drugmakers Eisai Inc. and Pfizer Inc. said on Saturday that government regulators have given them permission to make a larger dose of its Alzheimer's disease drug Aricept for patients who have already been taking ...

Recommended for you

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

Quantum Theory May Explain Wishful Thinking

April 14, 2009

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.